Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

RNA-seq of K562 cells treated with the FTO inhibitor CS2 compared to DMSO treated cells

ABSTRACT: RNA-seq of K562 cells treated with the FTO inhibitor CS2 compared to DMSO treated cells

PROVIDER: PRJEB60741 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	ERR11021079_1.fastq.gz	Fastqsanger.gz
	ERR11021079_2.fastq.gz	Fastqsanger.gz
	ERR11021080_1.fastq.gz	Fastqsanger.gz
	ERR11021080_2.fastq.gz	Fastqsanger.gz
	ERR11021081_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 12

Similar Datasets

RNA-seq of K562 cells treated with the FTO inhibitor CS2 compared to DMSO treated cells

Project description:Increased FTO expression has been connected to resistance to tyrosine kinase inhibitors in CML. To explore the therapeutic potential of targeting FTO in CML, we tested the FTO catalytic inhibitor in the K562 CML cell line. The RNA-seq was performed to identify relevant regulated genes.

2023-12-31 | E-MTAB-12774 | biostudies-arrayexpress

RNA-seq of K562 cells treated with the FTO inhibitor FB23-2

Project description:RNA-seq of K562 cells treated with the FTO inhibitor FB23-2

| PRJEB52885 | ENA

Differentially expressed genes analysis of wild type K562 cells treated with vandetanib and control (DMSO)

Project description:Purpose: The aim of this study was to evaluate the difference of mRNA and lncRNA in K562 cells treated with vandetanib (1.56 μM) and control (DMSO) by high-throughput sequencing results. Methods: Total RNA was extracted using the RNAfast200 kit according to the manufacturer’s protocol. Then, 200 ng RNA was sequenced with high throughput, and then pathway and GO analysis were used for comprehensive analysis. Finally, RT-PCR method was used to validate in large sample population. Results: High-throughput sequencing results showed that there were significant differences in mRNA and lncRNA in K562 cells treated with vandetanib (1.56 μM) and control (DMSO). Conclusions: It is the first time that we have used high-throughput sequencing to study the difference of mRNA and lncRNA in K562 cells treated with vandetanib (1.56 μM) and control (DMSO). The results of sequencing show that the expression of mRNA and lncRNA is quite different in K562 cells treated with vandetanib (1.56 μM) and control (DMSO).

2020-09-25 | GSE158518 | GEO

Sequencing of mRNA with N6-methyladenosine (m6A) modification in AML cells upon DMSO or FTO inhibitor treatment

Project description:To identify the potential mRNA targets of FTO inhibitor, we conducted m6A-seq with mRNA samples enriched from AML cells upon DMSO and FB23-2 (FTO inhibitor) treatment

2019-04-29 | GSE103496 | GEO

RNA seq with AML (NB4) cells upon FTO inhibition

Project description:To determine the potential targets of FTO and identify treatment significance of FTO inhibition in AML, we conducted transcriptome wide RNA seq with NB4 cells upon DMSO and FTO inhibitors (FB23 and FB23-2) treatment.

2019-04-29 | GSE103495 | GEO

Differentially expressed genes analysis of wild type K562 cells treated with vandetanib and control (DMSO)

Project description:Differentially expressed genes analysis of wild type K562 cells treated with vandetanib and control (DMSO)

| PRJNA665502 | ENA

Transcription profiling by array of human K562 cells treated with dasatinib

Project description:Total RNA from 1e7 K562 cells either mock-treated with DMSO or treated with 100nM dasatinib in two biological repeats for 3 hours

2009-04-02 | E-MEXP-1561 | biostudies-arrayexpress

RNA-seq of K562 cells treated with the FTO inhibitor FB23-2

Project description:FB23-2 inhibits proliferation of K562 cells. The RNA-seq was performed to identify relevant regulated genes.

2023-12-01 | E-MTAB-11751 | biostudies-arrayexpress

Glioblastoma cells treated with MI3 or DMSO

Project description:Glioblastoma cells treated with MI3 or DMSO

| PRJNA627969 | ENA

Human HepG2 cells: control DMSO vs. K7174-treated

Project description:Transcriptional profiling of human HepG2 cells comparing control DMSO-treated cells with K7174-treated cell

2014-08-01 | GSE48618 | GEO